Bispecific anti-CCL2 antibodies

US12103967B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Jens Fischer · Penzberg, DE
• Guy Georges · Habach, DE
• Anton Jochner · Penzberg, DE
• Gregor Jordan · Penzberg, DE
• Hubert Kettenberger · Munich, DE
• Joerg Moelleken · Penzberg, DE
• Tilman Schlothauer
• Georg Tiefenthaler · Sindelsdorf, DE
• Valeria Runza · Penzberg, DE
• Meher MAJETY · Penzberg, DE
• Martin Schaefer · Penzberg, DE
• Maria VIERT · Penzberg, DE
• Shu Feng · Singapore, SG
• Wei Shiong Adrian HO · Singapore, SG
• Siok Wan Gan · Singapore, SG
• Runyi Adeline LAM · Singapore, SG
• Michael GERTZ · Basel, CH

Key dates

• Filing date: Nov 14, 2023
• Grant date: Oct 1, 2024
• Expiry date: Nov 14, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/63
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.